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Ras proteins regulate signaling pathways important for cell growth, differentiation, and survival. Oncogenic mutant Ras pro-
teins are commonly expressed in human tumors, with mutations of the K-Ras isoform being most prevalent. To be active, K-Ras
must undergo posttranslational processing and associate with the plasmamembrane. We therefore devised a high-content
screening assay to search for inhibitors of K-Ras plasmamembrane association. Using this assay, we identified fendiline, an L-
type calcium channel blocker, as a specific inhibitor of K-Ras plasmamembrane targeting with no detectable effect on the local-
ization of H- and N-Ras. Other classes of L-type calcium channel blockers did not mislocalize K-Ras, suggesting a mechanism
that is unrelated to calcium channel blockade. Fendiline did not inhibit K-Ras posttranslational processing but significantly re-
duced nanoclustering of K-Ras and redistributed K-Ras from the plasmamembrane to the endoplasmic reticulum (ER), Golgi
apparatus, endosomes, and cytosol. Fendiline significantly inhibited signaling downstream of constitutively active K-Ras and
endogenous K-Ras signaling in cells transformed by oncogenic H-Ras. Consistent with these effects, fendiline blocked the prolif-
eration of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras. Taken together, these
results suggest that inhibitors of K-Ras plasmamembrane localizationmay have utility as novel K-Ras-specific anticancer
therapeutics.
Ras GTPases operate as molecular switches in signaling path-ways that control cell proliferation. Ras normally oscillates
between an active, GTP-bound state and an inactive, GDP-bound
state in a cycle that is tightly controlled by guanine nucleotide
exchange factors and GTPase-activating proteins. Oncogenic Ras
mutations occur in15% of all human tumors and directly con-
tribute to malignant transformation by locking Ras in the GTP-
bound state, leading to constitutive activation of downstream sig-
naling pathways. Activating point mutations have been reported
in all three ubiquitously expressed Ras isoforms, H-, N-, and K-
Ras, but the major clinical problem is K-Ras. Oncogenic K-Ras
mutations occur in 90% of pancreatic, 45% of colorectal, and 35%
of lung carcinomas (1–3).
Small-molecule inhibitors of kinases downstream of K-Ras
have been developed as anticancer therapeutics. Within the Raf-
mitogen-activated protein kinase (MAPK) cascade, potent inhib-
itors of BRaf, CRaf, and MEK are in clinical use (4–13). Although
very encouraging, the clinical responses to Raf inhibitors can be
relatively short-lived, with treatment failure and tumor progres-
sion occurring due to acquired resistance, primarily as a result of
secondary mutations in oncogenic BRaf or other proteins such as
N-Ras or MEK (14–16). In addition, while BRaf inhibitors inhibit
the activation of BRaf/MEK/extracellular signal-regulated kinase
(ERK) in BRaf mutant cell lines, they paradoxically activate MEK/
ERK signaling in cell lines with Ras mutations (17–20).
Approaches to directly target Ras have to date not been suc-
cessful. Ras proteins undergo posttranslational processing to gen-
erate a lipid-modified C terminus. The cysteine residue in the
C-terminal CAAX motif common to all Ras isoforms is isopreny-
lated by farnesyl protein transferase. Farnesylated Ras proteins
interact with the cytosolic surface of the endoplasmic reticulum
(ER), where the AAX motif is cleaved by Ras-converting enzyme 1
(Rce1). This is followed by carboxymethylation of the farnesylated
cysteine by isoprenyl cysteine carboxylmethyl transferase (Icmt)
(21). The weak membrane binding affinity provided by CAAX
processing is enhanced by a second signal comprising a C-termi-
nal polybasic domain in K-Ras and palmitoylation of one or two
cysteine residues (Cys181 and -184) in N- and H-Ras, respectively
(22–24). These second signals specify distinct ER-to-plasma
membrane trafficking routes: H- and N-Ras traffic via the classical
secretory pathway to the plasma membrane, while K-Ras transits
via a poorly understood, Golgi apparatus-independent route that
requires mitochondrial function and possibly cytosolic chaper-
ones (22, 23, 25, 26).
Since farnesylation is absolutely required for Ras biological ac-
tivity (27, 28), farnesyltransferase inhibitors (FTIs) were predicted
to be excellent candidates for anti-Ras drugs. However, in cells
treated with FTIs, K- and N-Ras are alternatively prenylated by
geranylgeranyl transferase 1 (GGTase1) and traffic normally from
the ER to the plasma membrane (29, 30). Geranylgeranylated
oncogenic K- and N-Ras are equally transforming as the cognate
farnesylated proteins (31, 32), and therefore FTIs have no clinical
utility in K- and N-Ras transformed cells. Inhibitors of Rce1 and
Icmt are under development, but since these agents will also target
CAAX processing of geranylgeranylated Rho family GTPases,
concerns for potential toxicity arise (33).
Notwithstanding the clinical failure of FTIs, since K-Ras must
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be localized to the plasma membrane to activate downstream ef-
fectors (34–36), inhibition of plasma membrane localization re-
mains a valid therapeutic approach to block signal transmission
by oncogenic K-Ras. We therefore devised a simple high-content
screen to search for inhibitors of K-Ras plasma membrane associ-
ation. We report here our results from screening the Prestwick
library, which comprises a large set of FDA-approved drugs. From
this library we identified fendiline as a specific inhibitor of K-Ras
plasma membrane localization that also inhibits K-Ras signal out-
put and blocks the proliferation of K-Ras-transformed tumor
cells.
MATERIALS AND METHODS
Materials. The Prestwick chemical library and fendiline hydrochloride
were purchased from Prestwick Chemicals (Illkirch, France). R and S
enantiomers of fendiline were synthesized by Aviara Pharmaceuticals,
Inc. (Houston, TX). Purity of compounds was confirmed by nuclear mag-
netic resonance (NMR) spectroscopy. All other drugs were purchased
from Sigma-Aldrich and were dissolved in dimethyl sulfoxide (DMSO).
Cell culture media and fetal bovine serum (FBS) were purchased from
HyClone. Penicillin-streptomycin was purchased from Invitrogen. Anti-
bodies against B-Raf (sc-5284), N-Ras (sc-31), and H-Ras (sc-520) were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-c-K-Ras
(R3400) and anti--actin (A1978) antibodies were from Sigma-Aldrich.
Anti-Ras (610001) and anti-Raf1 (610152) antibodies were obtained from
BD Transduction Laboratories (Lexington, KY). Anti-phospho-p44/42
mitogen-activated protein kinase (MAPK) (ERK1/2) (Thr202/Tyr204)
(9101), anti-phospho-Akt (pAkt) (Ser473) (9271), and anti-Akt (2920)
antibodies were from Cell Signaling Technology (Beverly, MA). Anti-
protein disulfide isomerase (anti-PDI) (ab2792), COX IV (ab33985), and
anti-58K Golgi protein (p58) (ab6284) antibodies were from Abcam
(Cambridge, MA). Mouse anti-green fluorescent protein (anti-GFP) an-
tibody for Western immunoblotting was from Sigma (G1546), and rabbit
anti-mGFP antibody for immunogold labeling was generated in-house.
K-Ras mouse ON-TargetPlus SMARTpool, ON-TargetPlus nontargeting
pool, DharmaFECT 1 small interfering RNA (siRNA) transfection re-
agent, and 5 siRNA buffer were purchased from Dharmacon (Lafayette,
CO). Recombinant MEK1(14-420) and ERK2(14-198) were purchased
from Millipore (Billerica, MA). RFP-KR plasmid was a kind gift from
Sergio Grinstein (Hospital for Sick Children, Toronto, Ontario, Canada).
Rac1 and Rap1A plasmids were kind gifts from Mark Phillips (New York
University School of Medicine, New York, NY).
Cell lines.BxPC3, HPAC, MOH, MiaPaCa-2, and MPanc96 cells were
kindly provided by Craig Logsdon, Hec-50 cells by Russell Broaddus,
KLE, ESS1, Ishikawa, and Hec-1a cells by Karen Lu, and HEC-1b cells by
Bryan Hennessey, all at MD Anderson Cancer Center, Houston, TX. All
other cell lines were purchased from the American Type Culture Collec-
tion (Manassas, VA). Madin-Darby canine kidney (MDCK) epithelial
cells and baby hamster kidney (BHK) cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM)– high-glucose medium supple-
mented with sodium pyruvate and 10% FBS or supplemented bovine calf
serum, respectively. KLE and Hec-50 cells were maintained in DMEM–
F-12 medium supplemented with 10% FBS. Hec-1a and Hec-1b cells were
grown in McCoy’s 5a medium supplemented with 10% FBS. Ishikawa
cells were maintained in minimal essential medium (MEM) supple-
mented with sodium pyruvate, nonessential amino acids, and 5% FBS,
and ESS-1 cells were grown in RPMI 1640 medium supplemented with
20% FBS. MPanc96 and CaCO-2 cells were grown in DMEM supple-
mented with 10% FBS, MiaPaCa-2 cells in DMEM supplemented with
10% FBS and 2.5% horse serum, and SK-CO-1 cells in Eagle’s MEM
supplemented with 10% FBS. SW116 and SW948 cells were grown in
Leibovitz’s L15 medium with 10% FBS. All other cell lines were grown in
RPMI 1640 supplemented with 10% FBS. SW116 and SW948 cells were
grown at 37°C without CO2. All other cell lines were grown at 37°C with
5% CO2. BHK cells were transfected using Lipofectamine (Invitrogen)
according to the manufacturer’s instructions. Where necessary, the cells
were serum starved for 2.5 h prior to harvest.
Preliminary and secondary drug screen. Wild-type MDCK cells or
MDCK cells stably expressing GFP appended with the C-terminal 24 or 25
amino acids of K-Ras or H-Ras (GFP-CTK and GFP-CTH, described
previously [22, 37]) were seeded in triplicate in 96-well plates (Matrical) at
a density of 30,000 cells/well and incubated for 24 h at 37°C. Prestwick
chemical library drugs were added at a concentration of 4g/ml (concen-
tration of DMSO, 1%) and incubated for a further 48 h. Cells were then
fixed with 4% paraformaldehyde and stored in phosphate-buffered saline
(PBS) at 4°C until imaged. Plates were imaged using a BD Pathway Bio-
imager. Images were acquired as a 3 by 3 montage with a 20 objective
lens using the GFP-confocal mode.
Fluorescence microscopy. Cells were grown on coverslips, treated
with 1% vehicle (DMSO) or various concentrations of drugs, and fixed
with 4% paraformaldehyde. The coverslips were mounted in Mowiol and
visualized by confocal microscopy (Nikon A1) using a 60 objective. For
quantification, the densitometric ratio of plasma membrane-localized K-
Ras versus total K-Ras was calculated using custom-written algorithms in
ImageJ software. For immunostaining, cells were fixed, permeabilized in
0.1% Triton in PBS for 10 min, and blocked with 0.2% bovine serum
albumin and 0.2% fish skin gelatin in PBS for 30 min. Primary and sec-
ondary antibodies were incubated for 1 h each, and then coverslips were
mounted in Mowiol.
Ras methylation assay. Confluent MDCK cells expressing GFP-K-
RasG12V or GFP-K-RasG12V,C185S were treated with vehicle (DMSO)
or fendiline (4 g/ml) for 48 h. For the final 18 h of drug treatment, cells
were labeled with 50 Ci/ml [methyl-3H]methionine in methionine-free
medium. GFP-K-RasG12V or GFP-K-RasG12V,C185S proteins were im-
munoprecipitated with GFP-trap (Chromotek, Germany) and separated
by SDS-PAGE. Radiolabeled Ras proteins were visualized using fluorog-
raphy with salicylate. Using the fluorograph as a guide, regions of gel
corresponding to GFP-Ras were cut out and treated overnight with 1 M
NaOH in a vapor phase equilibration assay to release and collect esterified
methyl groups (38, 39). The label released as methanol and label remain-
ing as methionine were determined by scintillation counting after neu-
tralization of alkali with HCl. The expected ratio of methyl-3H released as
methanol to methyl-3H remaining in the protein backbone is 11, which is
not significantly different from the values of 10.19 0.34 (mean stan-
dard error of the mean [SEM]; n 3) and 9.77 0.77 that we observed in
control and fendiline-treated cells, respectively. This assay confirms that
CAAX processing is completed normally in fendiline-treated cells.
K-Ras knockdown. BHK cells stably expressing GFP-tagged
H-RasG12V were transfected with the ON-Target K-Ras-specific siRNA
pool or nontargeting control siRNA pool (Dharmacon) according to the
manufacturer’s protocol. At 24 h posttransfection, the cells were treated
with vehicle or fendiline; 48 h later (72 h total knockdown time), the cells
were lysed for Western blot analysis.
Western blotting. For preparation of whole-cell lysates, cells were
lysed in buffer B (50 mM Tris [pH 7.5], 75 mM NaCl, 25 mM NaF, 5 mM
MgCl2, 5 mM EGTA, 1 mM dithiothreitol, 100 M NaVO4, 1% Nonidet
P-40 plus protease inhibitors). In cellular fractionation experiments, cells
were incubated in buffer A (10 mM Tris-HCl [pH 7.5], 25 mM NaF, 5 mM
MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 100 M NaVO4 plus pro-
tease inhibitors) for 30 min on ice and lysed by passing through a
27-gauge needle 30 times. The postnuclear supernatant was centri-
fuged at 100,000  g for 30 min, and the membrane pellet was resus-
pended in buffer A containing 1% Triton X-100. SDS-PAGE and Western
blotting with the specified antibody were performed using 20 g of each
whole-cell lysate/membrane (P100) fraction and volumes of soluble
(S100) fractions equal to that of the corresponding P100. Signal was de-
tected by enhanced chemiluminescence (SuperSignal; Pierce, Thermo
Fisher Scientific, Rockford, IL) and imaged by FluorChemQ (Alpha Ino-
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tech, San Leandro, CA). Quantification of intensities was performed using
FluorChemQ software.
Immuno-EMand spatial analysis. Immunoelectron microscopy (im-
muno-EM) and spatial analysis were conducted exactly as described pre-
viously (40, 41). Plasma membrane sheets were prepared, fixed, and la-
beled with affinity-purified anti-GFP antibody coupled directly to 4.5-nm
gold. Digital images of the immunogold-labeled plasma membrane sheets
were taken in a transmission electron microscope. Intact 1-m2 areas of
the plasma membrane sheet were identified using ImageJ, and the x-y
coordinates of the gold particles were determined. Ripley’s K function
(42) was calculated using the x-y coordinates and then standardized on
the 99% confidence interval (CI) for a random pattern (40, 41, 43). Boot-
strap tests to examine differences between replicated point patterns were
constructed exactly as described previously, and statistical significance
was evaluated against 1,000 bootstrap samples (43, 44).
Raf kinase assay. P100 fractions prepared from BHK cells were dis-
solved in buffer A containing 1% Triton X-100. Solubilized P100 fractions
were incubated with combinations of recombinant MEK and ERK in the
presence of Mg2-ATP (40 mM and 0.5 mM, respectively) (45). After 30
min at 30°C with vigorous shaking, the pMEK and pERK levels were
determined by quantitative Western blotting.
Proliferation assay. BxPC-3 (4 103 cells per well), MiaPaCa-2 (2
103), MOH (1.5 103), HPAC (7 103), MPanc96 (2 103), KLE (1
104), Hec-1A (5  103), Hec-1B (5  103), Ishikawa (5  103), ESS-
1(5  103), NCI 1975 (6  103), NCI H1299 (3  103), NCI H23 (1 
104), NCI H522 (5  103), SNU-C1 (4  103), NCI H508 (4  103),
CaCO-2 (5  103), SK-CO-1 (3  103), SW948 (4  103), and SW1116
(6  103) cells were seeded in 96-well plates. After 24 h, fresh growth
medium supplemented with 1% vehicle (DMSO), various concentrations
of fendiline, or U0126 was added and cells were grown for 48 h or 72 h.
Cell numbers were quantified using the CellTiter 96 AQueous One Solu-
tion cell proliferation assay (MTS) (Promega), according to the manufac-
turer’s protocol.
Viability assay. MDCK cells stably expressing GFP-K-RasG12V were
treated with 1% vehicle (DMSO) or various concentrations of fendiline
for 48 h. Cells were trypsinized and resuspended in medium. Ten micro-
liters of cell suspension was mixed with 10 l of 0.4% trypan blue, and
live/dead cell counts were obtained using Countess (Invitrogen).
Intracellular calciummeasurement. Intracellular calcium was mon-
itored in cultured cells using the Fura-2AM fluorescent indicator tech-
nique in ratiometric mode (46). Cells were grown on coverslips and
loaded with 5 M Fura-2AM in Hanks’ balanced salt solution (HBSS)
containing pluronic acid at 37°C for 30 min. Cells were then washed, and
the coverslips were attached to the bottom of a measurement cuvette filled
with HBSS and placed on the microscope stage of an InCyt Im Imaging
workstation (Intracellular Imaging, Inc.). Cells were imaged with a Nikon
Eclipse TS 100 inverted microscope using a 20 super fluor objective
(numerical aperture [NA]  0.75) and a 12-bit charge-coupled device
(CCD) camera (Pixel Fly, Cooke). Measurements were taken every 5 s
during the experiment. Drugs were added 1 min after starting the calcium
measurement, and then at 30 min and 32 min after addition of drugs, 10
M ionomycin and 50 mM EGTA were added sequentially to ensure
responsiveness of cells and to quench fluorescence, respectively. In 48-h
treatment experiments, cells were grown in the presence of drug for 48 h
and the drugs were also added to HBSS during calcium measurement.
Intracellular calcium levels were obtained by calculating the ratio of emis-
sion at 510 nm with excitation at 340 and 380 nm.
Statistical analysis. Prism (version 5.0c, GraphPad Software) was
used for statistical analysis.
RESULTS
Fendiline alters the plasmamembrane localization ofK-Ras but
not H-Ras. We constructed high-content screens to search for
chemicals that inhibit the plasma localization of Ras proteins. To
this end, we established MDCK cell lines stably expressing mGFP
targeted to the plasma membrane by the full C-terminal hyper-
variable region (HVR) of K-Ras4B (GFP-CTK) or H-Ras (GFP-
CTH) (22, 37) and MDCK cell lines stably expressing full-length
oncogenic mutant GFP-K-RasG12V (4B isoform, but here re-
ferred to as K-Ras) or GFP-H-RasG12V. MDCK cells were chosen
because the columnar morphology and basolateral distribution of
Ras facilitate automated confocal imaging. For primary screening
we used the cell lines GFP-CTK and GFP-CTH. The GFP-CTK
and GFP-CTH fusion proteins undergo the same posttransla-
tional processing and membrane trafficking as the cognate full-
length Ras protein (22, 23), but since they are biologically inert,
the morphology of the parental MDCK line is better preserved
than in cells expressing oncogenic mutant Ras.
MDCK cells dispensed in 96-well plates were grown in the
presence of each compound for 48 h before fixation and imaging.
This time frame was chosen to allow trafficking of newly synthe-
sized GFP-Ras proteins and turnover of GFP-Ras protein that was
already present when treatment started. As a positive control, cells
were treated with 10 M FTI-276, a farnesyl transferase inhibitor
that causes cytoplasmic localization of GFP-CTH but not GFP-
CTK (Fig. 1A). Images were scored for loss of plasma membrane
localization and intracellular accumulation of GFP. The aim of the
FIG 1 Fendiline mislocalizes GFP-K-RasG12V but not GFP-H-RasG12V. (A)
MDCK cells stably expressing GFP-CTK or GFP-CTH were seeded in 96-well
plates and treated with drug libraries for 48 h. Cells were then fixed and imaged
using a BD Pathway Imager in confocal mode. Shown are representative im-
ages of control cells treated with vehicle (DMSO) or 10 M FTI-276. (B)
Structure of fendiline hydrochloride. (C) MDCK or BHK cells stably express-
ing GFP-K-RasG12V or GFP-H-RasG12V were grown on coverslips and
treated with vehicle (DMSO) or fendiline (4g/ml 11M for MDCK and 6
g/ml  17 M for BHK cells) for 48 h. Cells were fixed and imaged using a
confocal microscope. Shown are representative images from 3 independent
experiments.
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screen was to identify compounds that selectively target K-Ras,
and thus we were interested in compounds that significantly mis-
localized GFP-CTK while having minimal or no effect on GFP-
CTH. Here we report our results of screening the Prestwick chem-
ical library, which comprises 1,120 small molecules that are
currently or have been in clinical use. All of these compounds are
therefore FDA-approved drugs. We screened the Prestwick library
at 4g/ml. Several drugs that are weak amphiphilic bases, includ-
ing chlorpromazine, scored weakly positive in the assay. The effect
of this class of drug on K-Ras localization has been described pre-
viously (47), and the mechanism of action is believed to involve
direct impairment of the electrostatic interaction of the K-Ras
polybasic domain with the negatively charged inner leaflet of the
plasma membrane. These compounds were not pursued further.
One other compound, fendiline (Fig. 1B), significantly mislocal-
ized GFP-CTK, had no significant effect on GFP-CTH, did not
inhibit CAAX processing (see Materials and Methods), and was
therefore selected for further study.
Fendiline selectivelymislocalizes K-Ras to endomembranes.
We first verified that fendiline was active against full-length
K-Ras in multiple cell types. MDCK and BHK cells expressing
full-length GFP-K-RasG12V and GFP-H-RasG12V were
treated with fendiline and examined by microscopy. Fendiline
significantly mislocalized GFP-K-RasG12V but had no effect
on the subcellular distribution of GFP-H-RasG12V (Fig. 1C).
Fendiline also had no effect on the plasma membrane localiza-
tion of GFP-N-RasG12V (not shown). We next evaluated the
efficacy of fendiline in a dose-response experiment and derived
a 50% inhibitory concentration (IC50) for K-RasG12V mislo-
calization of 9.64 0.42M (Fig. 2A and B). Importantly, even
at the highest concentration tested, fendiline did not compro-
mise cell viability as assayed by trypan blue exclusion (Fig. 2C);
thus, the loss of K-RasG12V from the plasma membrane is not
due to nonspecific cell toxicity. A time course study revealed
that the onset of action of fendiline is relatively slow; in cells
treated with fendiline, significant K-RasG12V mislocalization
required a 12-h incubation to manifest (Fig. 2D).
We examined the aberrant distribution of GFP-K-RasG12V
in fendiline-treated cells by costaining cells for PDI, p58, and
COX IV, which are ER, Golgi, and mitochondrial markers,
respectively. These experiments show that in fendiline-treated
cells, GFP-K-RasG12V mislocalizes in part to the ER and Golgi
apparatus but not detectably to mitochondria (Fig. 3). GFP-K-
RasG12V was also observed decorating cytoplasmic punctate
structures (Fig. 3), which were confirmed as endosomes by
electron microscopy (not shown). Cellular fractionation stud-
ies showed that treatment with fendiline increases the soluble,
cytosolic fraction of GFP-K-RasG12V but does not alter the
localization of GFP-H-RasG12V compared to that in the vehi-
cle-treated control cells (Fig. 4A). Taking the data in Fig. 1 to 4
FIG 2 Fendiline inhibits plasma membrane localization of K-Ras in a concentration-dependent manner. (A) MDCK cells stably expressing GFP-K-RasG12V
were grown on coverslips and treated for 48 h with vehicle (DMSO) or various concentrations of fendiline. Cells were fixed and imaged using a confocal
microscope. The ratio of plasma membrane K-Ras to total K-Ras was quantified by densitometric analysis using ImageJ software. (B) A representative dose-
response curve from 3 independent experiments. (C) MDCK cells stably expressing GFP-K-RasG12V were treated for 48 h with vehicle (DMSO) or various
concentrations of fendiline. The live/dead cell count was obtained using trypan blue staining. (D) MDCK cells stably expressing GFP-K-RasG12V were grown on
coverslips and treated for up to 48 h with vehicle (DMSO) or 10M fendiline. Cells were fixed and imaged using confocal microscope. Shown are representative
images from 3 independent experiments.
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together, we conclude that whereas some K-Ras is displaced to
the cytosol with fendiline treatment, the majority remains as-
sociated with intracellular membranes.
Effect of fendiline on K-Ras localization is Ca2 indepen-
dent. Fendiline is an inhibitor of L-type voltage-gated Ca2 chan-
nels (48). We therefore tested whether the effect of fendiline on
K-Ras localization was related to this known pharmacological ac-
tivity. We first examined whether other L-type Ca2 channel
blockers had an effect similar to that of fendiline; however, neither
nifedipine, verapamil, nor diltiazem, which belong to three differ-
ent classes of L-type Ca2 channel blocker, altered the localization
of GFP-K-RasG12V, as assayed by subcellular fractionation or cell
imaging (Fig. 4). Cells treated with fendiline show significant
reorganization of endomembrane morphology, irrespective of
whether the cells express GFP-Ras (Fig. 3); it is noteworthy, how-
ever, that incubation of cells in nifedipine, verapamil, diltiazem,
or the calcium ionophore ionomycin (Fig. 4B and data not shown)
did not cause any such change in endomembrane morphology
(Fig. 4B).
The consequence of inhibiting the activity of voltage-gated L-
type calcium channels is to blunt the rise in intracellular calcium
levels in excitable cells on membrane depolarization. The ex-
pected effect, if any, in fibroblasts is a reduction in calcium levels,
although somewhat paradoxically, fendiline has been reported to
weakly elevate intracellular Ca2 in certain nonexcitable cells (49–
52). Thus, to formally exclude a role for intracellular calcium, we
directly measured calcium levels in fendiline-treated cells by
quantitative imaging with Fura-2AM. As a positive control for
these experiments, we used the calcium ionophore ionomycin.
Figure 5A shows that 1 M and 10 M ionomycin acutely in-
creased intracellular Ca2 in BHK cells. The increase induced by
10M ionomycin was greater than with 1M ionomycin and was
sustained over the 30-min observation window; in contrast, the
weaker response to 1M ionomycin decayed significantly over 30
min. In contrast, fendiline induced no changes in intracellular
Ca2 under the same experimental conditions. Furthermore, no
changes in basal calcium levels were detected after 48 h of incuba-
tion in fendiline or 1 M ionomycin (Fig. 5B); the latter result is
FIG 3 Fendiline redistributes GFP-K-RasG12V to intracellular membranes. BHK cells stably expressing GFP-K-RasG12V or GFP-H-RasG12V (green) were
treated with vehicle (DMSO) or fendiline (17 M) for 48 h. Following treatment, cells were fixed and immunolabeled with antibodies against PDI (ER marker,
red), p58 (Golgi marker, red), or COX IV (mitochondrial marker, red). Shown are representative images from 3 independent experiments.
Fendiline, a Novel K-Ras-Speciﬁc Inhibitor
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not unexpected given the decaying response seen over a 30-min
interval (Fig. 5A). Similarly, none of the other Ca2 channel
blockers, i.e., nifedipine, verapamil, and diltiazem, had any effect
on basal Ca2 levels following 48 h of treatment (Fig. 5B). A 48-h
incubation in 10M ionomycin was toxic to cells, and so no Ca2
assay was possible.
Acute elevation of cytosolic Ca2 by ionophores such as iono-
mycin causes positively charged proteins that interact electrostat-
ically with the inner plasma membrane to dissociate through a
combination of cationic shielding of the negative surface charge of
the membrane, induction of PIP2 hydrolysis, and translocation of
phosphatidylserine to the outer leaflet (53). We next attempted to
correlate the measured changes in intracellular Ca2 induced by
ionomycin on the localization of GFP-K-RasG12V and an electro-
static charge sensor, RFP-KR, that is targeted to the inner plasma
membrane by a polybasic domain interspersed with aromatic
amino acids (53). Consistent with previous reports, at 2 min after
addition of ionomycin, GFP-K-RasG12V and RFP-KR were
both displaced from the plasma membrane to cytosol, corre-
sponding to the high intracellular Ca2 levels at this time point
(Fig. 5A and C). In cells treated with 10 M ionomycin, GFP-K-
RasG12V and RFP-KR remained cytosolic at 30 min after addi-
tion, but in cells treated with 1 M ionomycin, both proteins
returned predominantly to the plasma membrane after 30 min,
again correlating closely with the sustained elevation of Ca2with
10 M ionomycin and the decay in Ca2 levels with 1 M iono-
mycin (Fig. 5A and C). Unlike with ionomycin, acute exposure to
fendiline did not mislocalize GFP-K-RasG12V or RFP-KR (Fig.
5C). After 48 h of treatment, fendiline mislocalized GFP-K-
RasG12V but not RFP-KR, whereas 48 h of treatment with iono-
mycin did not affect the localization of either construct (Fig. 5C).
Taken together, the results in Fig. 4 and 5 fully recapitulate the
observations of Yeung et al. (53) that elevation of intracellular
calcium mislocalizes K-Ras by neutralizing plasma membrane 	
potential, but the results also show that the mechanism whereby
fendiline mislocalizes K-Ras is unrelated to changes in intracellu-
lar Ca2 or blockade of L-type Ca2 channels and therefore rep-
resents a novel, “off-target” effect of the drug. Since fendiline is
FIG 4 Fendiline but not other L-type calcium channel blockers mislocalize GFP-K-RasG12V. (A) BHK cells stably expressing GFP-K-RasG12V or GFP-H-
RasG12V were treated for 48 h with vehicle (DMSO), FTI-276 (10 M), fendiline (17 M), nifedipine (10 M), verapamil (10 M), diltiazem (10 M), or
ionomycin (1 M). Reported IC50s for calcium channel blockade are as follows: nifedipine, 0.05 to 10 M; verapamil, 0.2 to 1 M; diltiazem, 0.5 to 1 M; and
fendiline, 10 to 17 M (73–78). The concentrations of calcium channel blockers used in these experiments were close to or well above their established IC50s.
Following treatment, membrane (P100) and soluble (S100) protein fractions were prepared and analyzed by quantitative Western blotting. The total GFP-Ras
in P100 and S100 fractions of each sample was normalized to the vehicle-treated control. Representative anti-GFP Western blots of P100 and S100 fractions are
shown. The graph shows means SEMs from 4 independent experiments. Statistical significance was evaluated using Student’s t test (*, P
 0.05). The asterisk
indicates a significant reduction in P100 GFP-Ras (with concomitant increase in S100 GFP-Ras). (B) BHK cells stably expressing GFP-K-RasG12V were treated
with vehicle (DMSO), nifedipine (10M), or ionomycin (1M) for 48 h. Following treatment, cells were fixed and immunolabeled with antibodies against PDI
or p58.
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generally supplied as a racemic mixture, we synthesized and sep-
arately tested the activity of the purified R and S isomers. Interest-
ingly, we observed that R-fendiline was significantly more potent
than the racemic mixture, and, concordantly, pure S-fendiline
had very little effect on K-RasG12V localization (Fig. 6A). The
markedly different potencies of the two stereoisomers strongly
suggest that fendiline is binding to a specific target molecule to
effect K-Ras localization.
Fendiline targets other Ras-related proteins with polybasic
domains. To further explore the fendiline target sequences in K-
Ras, we examined efficacy against other Ras anchor constructs.
Our screening experiments showed that fendiline is active against
GFP-CTK and full-length GFP-K-RasG12V (Fig. 1 and 2). Figure
6B shows that fendiline also mislocalized wild-type K-Ras and
GFP targeted by the minimal C-terminal anchor of K-Ras (GFP-
tK). These mapping experiments identify the K-Ras polybasic do-
main as the target for fendiline activity. To determine if fendiline
sensitivity requires the presence of a specific prenyl group in ad-
dition to the polybasic domain, we assayed efficacy against gera-
nylgeranylated K-Ras. Geranylgeranylated K-Ras can be gener-
ated by replacing the wild-type CVIM CAAX motif of K-Ras with
CCIL, a bone fideGGTase1 substrate motif (32), or by treating cells
expressing K-Ras with a farnesyl transferase inhibitor to direct
aberrant processing of the wild-type CVIM motif by GGTase1 (29,
30). Figure 6B shows that geranylgeranylated K-Ras generated by
either method was mislocalized in fendiline-treated cells, indicat-
ing that the nature of the prenoid group on K-Ras is not important
for fendiline sensitivity. Previous studies have shown that protein
kinase C (PKC)-mediated phosphorylation of Ser181 in the C-ter-
minal polybasic domain causes dissociation of K-Ras from the
plasma membrane and association with endomembrane (54). We
therefore tested the effect of fendiline on K-RasG12V,S181A, a
mutant that is resistant to PKC phosphorylation. As with
K-RasG12V, fendiline treatment mislocalized K-RasG12V,S181A
to intracellular membranes (Fig. 6C), indicating that the mecha-
nism by which fendiline causes K-Ras mislocalization does not
involve phosphorylation of Ser181.
Since fendiline caused the mislocalization of the K-Ras C-terminal
FIG 5 The mechanism of action of fendiline is calcium independent. (A) BHK cells stably expressing GFP-K-RasG12V were grown on coverslips and loaded with
5M Fura2-AM. Cells were then washed and placed on the microscope stage of an InCyt Im Imaging workstation, and measurements were taken every 5 s during
the experiment. Vehicle (DMSO) or drugs were added after 1 min (indicated in tracing as “1”); 10 M ionomycin and 50 mM EGTA were added at 30 min and
32 min to ensure responsiveness of cells and to quench fluorescence, respectively (indicated in tracing as “2” and “3,” respectively). Intracellular calcium levels
were obtained by calculating the ratio of emission at 510 nm with excitation at 340 and 380 nm. Shown are the average tracings from 30 individual cells. (B)
Wild-type (WT) BHK cells or BHK cells stably expressing GFP-K-RasG12V were grown in the presence of drugs for 48 h and basal calcium levels measured in
the continuing presence of drugs. The graph shows means  SEMs from 3 independent experiments. (C) BHK cells grown on coverslips were transiently
transfected with RFP-KR or GFP-K-RasG12V, treated with vehicle (DMSO), ionomycin (1M or 10M), or fendiline (17M) for 2 min, 30 min or 48 h, fixed,
and imaged using a confocal microscope. Shown are representative images from 3 independent experiments.
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anchor constructs GFP-tK and GFP-CTK, we next determined if fen-
diline mislocalizes other Ras-related proteins with C-terminal poly-
basic domains. Figure 6D shows that fendiline treatment caused re-
distribution of the Rho family protein GFP-Rac1 and the Ras family
protein GFP-Rap1A from the plasma membrane to intracellular
membranes. Rac1 and Rap1A are both anchored by a combination of
a polybasic domain and a geranylgeranyl group, but recent studies
have shown that Rac1 is additionally palmitoylated on a cysteine res-
idue adjacent to the polybasic domain (55). The second signal for
plasma membrane targeting of Rac1 is very similar to that of the
alternative K-Ras isoform K-Ras4A; the C-terminal hypervariable re-
gion of K-Ras4A has a 6 net positive charge, compared to a 5 net
positive charge in Rac1, and both are singly palmitoylated (Fig. 6E).
And as with GFP-Rac1, GFP-K-Ras4A was significantly mislocalized
in fendiline-treated cells (Fig. 6B and D). As shown earlier, fendiline
did not mislocalize the membrane potential probe RFP-KR (53)
(Fig. 5C and 6D). Taken together these results therefore indicate that
in addition to a polybasic domain, the additional presence of a prenyl
anchor may also be required for fendiline-mediated action.
Fendiline impairs K-Ras plasmamembrane interactions. To
further quantify the reduction in K-Ras interaction with the
plasma membrane, we prepared intact plasma membrane sheets
from BHK cells expressing GFP-K-RasG12V or GFP-H-RasG12V
treated with vehicle or fendiline. The plasma membrane sheets
were labeled with anti-mGFP conjugated to 4.5-nm gold and then
imaged by electron microscopy. The total amount of gold labeling
of the fendiline-treated K-RasG12V sheets was reduced by50%
from that of the untreated control cells (Fig. 7B). Since the EM
method detects only plasma membrane bound Ras, this result
provides accurate quantitation of the extent of loss of K-Ras from
the plasma membrane that was evident on confocal imaging. Spa-
tial statistical analysis of the immunogold point patterns further
showed that fendiline reduced the extent of K-RasG12V nanoclus-
tering (Fig. 7A). In contrast, fendiline treatment increased the
total amount of H-RasG12V on the plasma membrane (Fig. 7B)
but again modestly decreased the extent of H-RasG12V nanoclus-
tering (Fig. 7A).
Fendiline abrogates signaling downstream of constitutively
active K-Ras. Next, we explored the relationship between mislo-
calization of K-Ras by fendiline and signal output. We first ana-
lyzed Raf kinase activity in MDCK and BHK cells expressing full-
length GFP-K-RasG12V. Raf kinase activity, measured by a
FIG 6 Fendiline targets Ras proteins with polybasic domains. (A) MDCK cells stably expressing GFP-K-RasG12V were grown on coverslips and treated for 48
h with vehicle (DMSO) or racemic, R-, or S-fendiline (6M). Cells were fixed and imaged using a confocal microscope. (B) BHK cells grown on coverslips were
transiently transfected with GFP-K-Ras4B, GFP-K-Ras4B CCIL, GFP-K-Ras4A, or GFP-tK, treated for 48 h with vehicle (DMSO) or fendiline (17M), fixed, and
imaged using a confocal microscope. GFP-K-Ras4B-transfected cells were also treated with a combination of FTI (10M) and vehicle (DMSO) or fendiline (17
M). (C) BHK cells grown on coverslips were transiently transfected with GFP-K-RasG12V or GFP-KRasG12V,S181A, treated for 48 h with vehicle (DMSO) or
fendiline (17M), fixed, and imaged using a confocal microscope. (D) BHK cells grown on coverslips were transiently transfected with GFP-Rac1, GFP-Rap1A,
or RFP-KR and treated for 48 h with vehicle (DMSO) or fendiline (17 M). Cells were fixed and imaged using a confocal microscope. (E) C-terminal amino
acid sequences of K-Ras4A, K-Ras4B, Rac1, and Rap1A and the targeting sequence of the KR probe. Basic residues are shown in blue, acidic residues in red, and
palmitoylated cysteine residues in green, and aromatic residues in KR, which contribute to membrane anchoring of the probe, are underlined.
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coupled MEK/ERK assay, was reduced by 60% when the cells
were treated with fendiline (Fig. 8A). A dose-response analysis of
fendiline on BHK cells transformed by GFP-K-RasG12V returned
IC50s of 9.49 0.64 and 6.97 1.24 M, respectively, for fendi-
line-mediated inhibition of ERK and Akt activation (Fig. 8B).
These IC50s are very similar to the IC50 derived from the K-Ras
mislocalization assay (Fig. 2), consistent with a mechanistic link
between displacement from the plasma membrane and abroga-
tion of signal output. Furthermore, none of the other Ca2 chan-
nel blockers we tested, nor ionomycin, had any effect on pMEK,
pERK, and pAkt levels in K-Ras-transformed cells (Fig. 8C). In
order to examine whether fendiline specifically inhibits K-Ras, we
assayed cells expressing constitutively active CRaf (Flag-Raf-
YY340/341DD) or the more clinically relevant constitutively ac-
tive BRaf mutant (myc-BRaf-V600E). Signaling downstream of
CRaf-DD was less robust than from BRaf-V600E. Fendiline had
no effect on signaling downstream of constitutively active CRaf
but partially inhibited signaling downstream of constitutively ac-
tive BRaf (Fig. 9), consistent with the requirement for constitu-
tively active BRaf to be recruited to the plasma membrane by Ras
for full activation of MAPK (56). Taken together, these data pro-
vide strong evidence that fendiline inhibits MAPK signaling at the
level of Ras.
To further examine the isoform specificity of fendiline, we de-
termined its effect on signaling in cells expressing constitutively
active H- or N-Ras. Unexpectedly, fendiline significantly reduced
pMEK, pERK, and pAkt levels in BHK and MDCK cells expressing
FIG 7 Fendiline inhibits GFP-K-RasG12V plasma membrane association and
nanoclustering. Plasma membrane sheets were generated from BHK cells tran-
siently transfected with GFP-K-RasG12V or GFP-H-RasG12V and treated
with vehicle (DMSO) or fendiline (17 M) for 48 h. Plasma membrane sheets
were labeled with anti-GFP antibody conjugated to 4.5-nm gold and imaged in
an electron microscope. Images were processed to remove background, and
the x-y coordinates of all the gold particles in a given area were determined. (A)
Ripley’s K-function analysis was used to determine whether the observed gold
pattern was random, clustered, or dispersed. Values of L(r) r that are above
the 99% confidence interval (CI) (normalized to 1) indicate significant clus-
tering at that value r, values of L(r)  r in the interval 1 to 1 indicate a
random pattern, and values of L(r) r below1.0 indicate significant disper-
sal. Univariate K-functions are weighted means (n  8) standardized on the
99% CI for a random pattern. Significant differences from the control pattern
for fendiline-treated cells were assessed using bootstrap tests; the P values are
P  0.001 and P  0.028 for K-RasG12V and H-RasG12V, respectively. (B)
Average gold density on the immunolabeled plasma membrane sheets used for
the analysis in panel A (mean  SEM; n  8). The statistical significance of
differences in gold labeling density was evaluated using Student’s t test (*, P

0.05).
FIG 8 Fendiline inhibits Raf kinase activity and signaling downstream of
oncogenic K-Ras. (A) BHK cells stably expressing K- or H-RasG12V were
treated for 48 h with vehicle (DMSO) or fendiline (17M). Raf kinase activity
in the P100 fractions prepared from the cells was measured in a coupled MEK/
ERK kinase assay. The graph shows means  SEMs from 3 independent ex-
periments. Raf kinase activity was normalized to the corresponding vehicle-
treated sample. (B) MDCK cells stably expressing K-RasG12V were treated
with vehicle (DMSO) or various concentrations of fendiline for 48 h. Follow-
ing treatment, whole-cell lysates were prepared and pERK and pAkt levels were
measured by quantitative Western blotting. Representative Western blots and
a representative dose-response curve from 3 independent experiments are
shown; pERK and pAkt levels were normalized to the control sample. (C) BHK
cells stably expressing GFP-K-RasG12V were treated with vehicle (DMSO),
FTI-276 (10M), fendiline (17M), nifedipine (10M), verapamil (10M),
diltiazem (10 M), or ionomycin (1 M) for 48 h. Following treatment, P100
and S100 fractions were prepared. pMEK and pERK levels in the S100 fraction
and pAkt levels in the P100 fraction were measured by quantitative Western
blotting. Actin and Akt were used as loading controls. Representative Western
blots are shown.
Fendiline, a Novel K-Ras-Speciﬁc Inhibitor
January 2013 Volume 33 Number 2 mcb.asm.org 245
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
constitutively active H-RasG12V (Fig. 10A and data not shown)
but had no effect on signaling downstream of oncogenic N-Ras
(data not shown). Previous studies have reported that H-Ras-me-
diated regulation of the MAPK cascade is in part dependent upon
an autocrine mechanism (57–61). We therefore tested the hypoth-
esis that oncogenic H-Ras signaling occurs in part through endog-
enous K-Ras. Using siRNA, we knocked down the expression of
endogenous K-Ras in BHK cells expressing H-RasG12V and
quantified pERK levels. Knockdown of endogenous K-Ras signif-
icantly reduced pERK levels in H-RasG12V-expressing cells and
rendered the cells resistant to further inhibition of pERK levels on
treatment with fendiline (Fig. 10B). These data suggest that en-
dogenous K-Ras is required for the activation of signaling cascades
by oncogenic H-Ras and that fendiline inhibits signaling down-
stream of H-RasG12V due to its inhibitory effect on endogenous
K-Ras.
Fendiline inhibits proliferation of K-Ras-transformed tu-
mor cell lines. Finally, we tested the efficacy of fendiline to inhibit
proliferation of a panel of 21 pancreatic, endometrial, lung, and
colon tumor cell lines; the panel was chosen to include multiple
examples of cell lines that express wild-type and oncogenic mu-
tant K-Ras (Fig. 11A). The results show that regardless of the ori-
gin of the tumor, fendiline more potently inhibited the prolifera-
tion of tumor cells that express oncogenic mutant K-Ras than
tumor cells that express wild-type K-Ras. One exception within
the panel was the CaCO-2 colon cancer cell line, which despite
being wild type for K-Ras was potently inhibited by fendiline.
Interestingly, quantitative immunoblotting showed that K-Ras
expression was 16-fold higher in the CaCO-2 cells than in
SNU-C1 cells that were also wild type for K-Ras yet unresponsive
to fendiline (Fig. 11B). It is possible that the enhanced K-Ras sig-
naling expected from enhanced K-Ras expression accounts for the
sensitivity of CaCO-2 cells to fendiline.
We have shown that fendiline, by acting at the level of Ras,
simultaneously inhibits multiple Ras effector pathways. We there-
fore investigated whether this mechanism of blocking Ras signal-
ing is advantageous in blocking K-Ras-driven cell proliferation.
K-Ras-transformed Hec1A cells were incubated with increasing
concentrations of fendiline or the MEK inhibitor U0126 (Fig. 12)
and the effect on cell growth and pERK levels monitored. Inter-
FIG 9 Fendiline inhibits signal transmission at the level of Ras. Whole-cell
lysates from serum-starved BHK cells transiently transfected with vector con-
trol, FLAG-CRaf-DD-CAAX, or Myc-BRaf V600E and treated for 48 h with
vehicle (DMSO) or fendiline (17 M) were analyzed by quantitative Western
blotting. Representative Western blots of CRaf, pMEK, pERK, and actin (load-
ing control) are shown. The graphs show means SEMs from 3 or 4 indepen-
dent experiments. pERK and pMEK levels were normalized to the vector-
transfected, vehicle-treated control sample. Statistical significance was
calculated using Student’s t test (*, P
 0.05).
FIG 10 H-RasG12V signals through endogenous K-Ras. (A) BHK cells stably
expressing GFP-H-RasG12V were treated for 48 h with vehicle (DMSO), FTI-
276 (10 M), fendiline (17 M), nifedipine (10 M), verapamil (10 M),
diltiazem (10M), or ionomycin (1M). Following treatment, P100 and S100
fractions were prepared. pMEK and pERK levels in the S100 fraction and pAkt
levels in the P100 fraction were measured by quantitative Western blotting.
Actin and Akt were used as loading controls. Representative Western blots are
shown. (B) BHK cells stably expressing GFP-H-RasG12V were transfected
with control nontargeting siRNA or K-Ras siRNA, each containing a pool of 4
siRNAs. At 24 h after transfection, cells were treated with vehicle (DMSO) or
fendiline (17 M) for a further 48 h. Whole-cell lysates were prepared from
serum-starved cells and analyzed by quantitative Western blotting. The K-Ras
siRNA pool specifically knocks down the expression of endogenous K-Ras
without affecting the expression of endogenous H- or N-Ras or the ectopically
expressed GFP-H-RasG12V. Representative Western blots are shown. The
graphs show means  SEMs from 6 independent experiments. pERK levels
were normalized to the control siRNA-transfected, vehicle-treated control
sample. Statistical significance was evaluated using Student’s t test (*, P 

0.05).
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estingly, although U0126 was much more potent than fendiline at
inhibiting MAPK activation, fendiline was significantly more po-
tent than U0126 at inhibiting cell proliferation (Fig. 12). Taken
together, these results suggest that fendiline inhibits K-Ras-medi-
ated proliferation of cells by blocking more than the Raf-MEK-
ERK signaling axis and that concordant inhibition of parallel Ras
effector pathways delivers important synergistic effects in abro-
gating tumor cell growth.
DISCUSSION
In this study, we used high-content screening to identify small
molecules that inhibit the trafficking or plasma membrane local-
ization of K-Ras. We show that fendiline at therapeutic concen-
trations (62) significantly mislocalizes K-Ras and inhibits K-Ras
signaling. Cellular fractionation coupled with fluorescence and
electron microscopy imaging shows that whereas some K-Ras ap-
pears in the cytosol on fendiline treatment, the majority of K-Ras
displaced from the plasma membrane is associated with intracel-
lular membranes, including Golgi apparatus, ER, and endosomes.
Since K-Ras prenylation and methylation are not affected by fen-
diline treatment, we conclude that fendiline must inhibit K-Ras
transport or plasma membrane interactions distal to CAAX pro-
cessing. Importantly, fendiline specifically affects K-Ras plasma
membrane localization and has no significant effect on the subcel-
lular distribution of H-Ras or N-Ras.
Fendiline is an FDA-approved, albeit now clinically obsolete,
FIG 11 Fendiline selectively inhibits proliferation of tumor cell lines expressing oncogenic mutant K-Ras. (A) A panel of wild-type (WT) or oncogenic mutant
(Mut) K-Ras-expressing tumor cells were seeded in 96-well plates and treated for 72 h with vehicle (DMSO) or various concentrations of fendiline. The number
of viable cells was quantified (absorbance at 490 nm) using the CellTiter 96 AQueous One Solution cell proliferation assay kit (Promega). The graphs show
relative mean numbers of viable cells SEMs from 3 independent experiments. Cell lines expressing oncogenic mutant K-Ras are shown in red, and cell lines that
express wild-type K-Ras are shown in black. NCI H1299 cells (shown in blue) express wild-type K-Ras but mutant N-Ras. CaCO-2 cells (shown in green)
overexpress wild-type K-Ras. (B) K-Ras levels in whole-cell lysates of SNU-C1, CaCO-2, and SK-CO-1 cells were quantified by Western blotting. The graphs show
means SEMs for 3 isolates of each cell line (indicated as 1, 2, and 3). K-Ras expression was normalized to the SNU-C1 sample.
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L-type calcium channel blocker. Our data strongly suggest, how-
ever, that the effect of fendiline on K-Ras targeting is unrelated to
blockade of calcium channels, since three other classes of L-type
calcium channel blocker, i.e., diltiazem, verapamil, and nifedi-
pine, had no effect on K-Ras plasma membrane targeting. More-
over, while we fully replicated here all of the previously reported
experiments of Yeung et al. (53) showing that acute elevation of
intracellular Ca2 levels dissociates K-Ras from the plasma mem-
brane, neither acute nor chronic exposure to fendiline induced
any detectable change in intracellular Ca2 levels over time scales
when K-Ras mislocalization was clearly evident. Taken together,
these observations provide compelling evidence that the mecha-
nism of action of fendiline on K-Ras targeting is calcium indepen-
dent, is unrelated to the known pharmacology of the drug, and is
therefore a novel off-target effect of the compound.
Previous work has shown that K-Ras can be extensively redis-
tributed to endomembranes as a result of PKC-dependent phos-
phorylation of S181 in the polybasic domain. Operation of a
farnesyl-electrostatic switch, results in reduced affinity of phos-
phorylated K-Ras for the negatively charged plasma membrane
and retargeting to ER and mitochondria (54, 63). Several lines of
evidence suggest that fendiline is not operating via this mecha-
nism. We did not see colocalization of K-Ras with the mitochon-
drial marker COX IV in fendiline-treated cells; a K-Ras mutant
with the major PKC phosphorylation site removed, K-RasS181A,
was equally responsive to fendiline, and fendiline did not induce
apoptosis of K-RasG12V-transformed cells, a phenotype associ-
ated with PKC-induced K-Ras redistribution (54).
Some clues to a biophysical mechanism of action are suggested
by the C-terminal mapping experiments and sensitivity of other
Ras-related proteins to fendiline. GFPs targeted by the minimal
membrane anchor (GFP-tK) or the extended hypervariable region
of K-Ras (GFP-CTK) as well as full-length wild-type and mutant
K-Ras were all sensitive to fendiline, irrespective of the nature of
the prenoid group attached to the CAAX box. These results iden-
tify a plasma membrane anchor comprising a prenylated polyba-
sic domain as the minimal determinant for fendiline sensitivity.
This conclusion is supported by the sensitivity of Rap1A and Rac1,
which are also primarily anchored by a prenylated polybasic do-
main. By extrapolation, given the observed sensitivity to fendiline,
we conclude that the charged hypervariable region of K-Ras4A, in
addition to the palmitate group, is also critical for membrane an-
choring of this Ras isoform. Together these results imply that fen-
diline perturbs the electrostatic interactions of polybasic domains
with the electronegative inner leaflet of the plasma membrane
and/or perturbs the trafficking of prenylated polybasic domain-
targeted Ras proteins. The latter option cannot be discounted be-
cause plasma membrane targeting of RFP-KRwas unaffected by
fendiline; this electrostatic charge probe is anchored by a polybasic
domain that has a net charge similar to that of K-Ras but in place
of a prenyl group contains three aromatic amino acids that inter-
calate into the lipid bilayer and provide additional membrane
binding.
Additional mechanisms that are potentially involved in K-Ras
plasma membrane targeting include some form of directed ER-to-
plasma membrane trafficking pathway and/or a mechanism to
trap K-Ras delivered to the plasma membrane by random diffu-
sion. Once at the plasma membrane, 	 potential and availability of
nanocluster scaffolds such as galectin-3 positively regulate K-Ras
plasma membrane binding. Scaffolding proteins such as galec-
tin-3 play a role in maintaining K-Ras on the plasma membrane.
The reduced plasma membrane K-Ras clustering and plasma
membrane localization observed in fendiline-treated cells is a par-
tial phenocopy of both galectin-3 knockdown and treatment with
S-trans,trans-farnesyl thiosalicylic acid (FTS), which accelerates
the release of activated K-Ras from the plasma membrane by com-
peting with K-Ras for a predicted prenyl residue binding pocket in
galectin-3 (64, 65). We did also detect modest effects of fendiline
on H-Ras clustering but with no effect on overall H-Ras plasma
membrane binding, a result consistent with perturbation of lipid
anchor/lipid bilayer interactions as recently observed with non-
steroidal anti-inflammatory drugs (NSAIDs) (66, 67). Two other
proteins, PDE and PRA1, influence the dynamics of K-Ras
plasma membrane interactions. PDE increases plasma mem-
brane targeting of K-Ras by solubilizing K-Ras from endomem-
branes and facilitating cytosolic diffusion (25). Reduced PDE
expression, however, also mislocalizes H-Ras, an effect not seen
with fendiline treatment, making it unlikely that fendiline acts as a
PDE inhibitor. PRA1 increases the rate of dissociation of K-Ras
from the plasma membrane (68), and thus inhibition of PRA1-K-
Ras interactions would enhance, not reduce, K-Ras plasma mem-
brane targeting.
Whatever the precise mechanism of action of the drug, we
show that fendiline-induced K-Ras mislocalization abrogates sig-
naling downstream of oncogenic K-Ras. Specifically, we show that
fendiline inhibits K-Ras-dependent Raf-MAPK and PI3K-AKT
signaling; we did not assay other effector pathways, but given that
fendiline directly targets K-Ras, it is reasonable to presume that
signaling through all K-Ras effector pathways will be inhibited. In
the case of Ras-dependent Rac activation, the ability of fendiline to
mislocalize Rac1 may lead to an additional block in this pathway.
The synergistic effect of simultaneous inhibition of multiple Ras
effector pathways would be expected to translate into potent an-
FIG 12 Fendiline is more potent than a MEK inhibitor at blocking prolifera-
tion of a tumor cell line expressing oncogenic mutant K-Ras. Hec-1a cells were
treated for 48 h with vehicle (DMSO) and various doses of fendiline or U0126.
Medium was replaced with fresh U0126 every 24 h, whereas only a single dose
of fendiline was added for the duration of the 48 h of incubation. The number
of viable cells was quantified (absorbance at 490 nm) using the CellTiter 96
AQueous One Solution cell proliferation assay kit (Promega). The graph
shows means  SEMs from 3 independent experiments. Cell numbers were
normalized to the corresponding vehicle-treated control. Statistical signifi-
cance was calculated using Student’s t test (*, P
 0.05). The pERK levels in cell
lysates were quantified using Western blotting, and relative levels are shown.
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titumor activity. We provide preliminary evidence for this con-
cept by showing that fendiline is a much more potent inhibitor of
tumor cell growth than a simple MEK inhibitor that solely blocks
MAPK activation. More broadly, we show that fendiline potently
inhibits the growth of a large set of pancreatic, colon, endometrial,
and lung tumor cell lines transformed by oncogenic mutant K-Ras
but generally has little or no activity against tumor cell lines that
express wild-type K-Ras. Other studies have reported that fendi-
line causes cell death of bladder transitional carcinoma cells, PC3
human prostate cancer cells, and human oral cancer cells (49,
50, 69).
Fendiline may have additional utility as a chemotherapeutic
agent in combination therapy. For example, mTOR inhibitors,
including rapamycin and derivatives CCI-779, AP23573, and
RAD001, are currently in clinical trials (70). However, clinical use
is somewhat limited due to activation of the MAPK cascade in cells
treated with mTOR inhibitors through a feedback loop that de-
pends on an S6K-PI3K-Ras pathway (71). Using fendiline in com-
bination with mTOR inhibitors may abrogate the induced activa-
tion of MAPK signaling and improve treatment efficacy. Our
ongoing work with endometrial cancer cell lines supports this hy-
pothesis. Similarly, we showed recently that fendiline prevents
paradoxical activation of MEK/ERK signaling in Ras transformed
cells treated with BRaf inhibitors because of the ability of fendiline
to reduce K-Ras levels on the plasma membrane and abrogate
K-Ras nanoclustering (17). Finally, we show here that fendiline
also inhibits signaling in oncogenic H-Ras-expressing cells, most
likely though inhibition of endogenous K-Ras signaling. Previous
studies have shown that oncogenic H-Ras requires autocrine sig-
naling to mediate many of its oncogenic properties, through the
release of transforming growth factor  (TGF-) (57–61) and
other epidermal growth factor receptor (EGFR) ligands, including
amphiregulin, heparin binding EGF (HB-EGF), and -cellulin
(72). Our study provides new evidence that these autocrine-sig-
naling loops are actually critically dependent on the K-Ras iso-
form.
In summary, taking together the effects of fendiline on K-Ras
localization, signaling, and biological function, we propose that
small molecules which inhibit the plasma localization of K-Ras
merit serious consideration as anti-Ras therapeutics.
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